Bridgeway Capital Management, LLC Cor Medix Inc. Transaction History

Bridgeway Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.64 - $8.23 $91,000 - $205,750	-25,000 Reduced 16.59%	125,700 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$3.0 - $4.01 $45,000 - $60,150	15,000 Added 11.05%	150,700 $566,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $181,800 - $225,230	50,500 Added 59.27%	135,700 $502,000
Q2 2023 Aug 14, 2023	SELL	$3.94 - $5.8 $164,298 - $241,860	-41,700 Reduced 32.86%	85,200 $337,000
Q1 2023 May 15, 2023	SELL	$3.22 - $4.61 $80,500 - $115,250	-25,000 Reduced 16.46%	126,900 $525,000
Q2 2022 Aug 15, 2022	SELL	$2.73 - $5.61 $50,232 - $103,224	-18,400 Reduced 10.8%	151,900 $611,000
Q3 2021 Nov 15, 2021	BUY	$4.46 - $7.11 $129,340 - $206,190	29,000 Added 20.52%	170,300 $792,000
Q2 2021 Aug 16, 2021	SELL	$6.05 - $10.09 $71,390 - $119,062	-11,800 Reduced 7.71%	141,300 $969,000
Q1 2021 May 17, 2021	BUY	$6.84 - $17.58 $376,200 - $966,899	55,000 Added 56.07%	153,100 $1.53 Million
Q4 2019 Feb 14, 2020	BUY	$4.96 - $7.75 $146,816 - $229,400	29,600 Added 43.21%	98,100 $714,000
Q1 2019 May 15, 2019	BUY	$6.95 - $13.25 $476,075 - $907,625	68,500 New	68,500 $647,000

165

29.2M

475K

777K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $474M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.